WuXi AppTec (603259) investor relations material

Executive summary

• Delivered strong revenue and profit growth, with revenue up 38.93% and net profit attributable to shareholders up 29.43% year-over-year for the first half of 2026, driven by robust client demand and efficient execution.

• Maintained global leadership in integrated CRDMO services, expanding capacity and capabilities to meet rising customer needs across chemistry, testing, and biology segments.

• Announced a mid-year cash dividend of RMB 5.10 per 10 shares, totaling RMB 1.51 billion, and completed a significant H-share repurchase.

Financial highlights

• Revenue reached RMB 28.90 billion, up 38.93% year-over-year; net profit attributable to shareholders was RMB 11.08 billion, up 29.43%.

• Gross profit rose 68.5% to RMB 15.58 billion, with gross margin improving by 9.46 percentage points to 53.9%.

• Operating cash flow increased 30.52% to RMB 9.70 billion.

• Adjusted net profit (excluding non-recurring items) grew 89.39% year-over-year.

• Basic EPS was RMB 3.80, up 26.25% year-over-year.

Outlook and guidance

• Upgraded full-year 2026 revenue guidance to RMB 58.5–60.5 billion, with expected 35–39% growth in continuing operations.

• Capital expenditure guidance raised to RMB 7.5–8.5 billion to accelerate global capacity expansion.

• Adjusted free cash flow forecast increased to RMB 13.5–14.5 billion.